| Literature DB >> 24747400 |
Tobias Deuse1, Xiaoqin Hua2, Dong Wang2, Lars Maegdefessel3, Joerg Heeren4, Ludger Scheja4, Juan P Bolaños5, Aleksandar Rakovic6, Joshua M Spin7, Mandy Stubbendorff2, Fumiaki Ikeno7, Florian Länger8, Tanja Zeller9, Leonie Schulte-Uentrop10, Andrea Stoehr11, Ryo Itagaki2, Francois Haddad7, Thomas Eschenhagen11, Stefan Blankenberg9, Rainer Kiefmann10, Hermann Reichenspurner12, Joachim Velden13, Christine Klein6, Alan Yeung7, Robert C Robbins14, Philip S Tsao15, Sonja Schrepfer16.
Abstract
Despite the introduction of antiproliferative drug-eluting stents, coronary heart disease remains the leading cause of death in the United States. In-stent restenosis and bypass graft failure are characterized by excessive smooth muscle cell (SMC) proliferation and concomitant myointima formation with luminal obliteration. Here we show that during the development of myointimal hyperplasia in human arteries, SMCs show hyperpolarization of their mitochondrial membrane potential (ΔΨm) and acquire a temporary state with a high proliferative rate and resistance to apoptosis. Pyruvate dehydrogenase kinase isoform 2 (PDK2) was identified as a key regulatory protein, and its activation proved necessary for relevant myointima formation. Pharmacologic PDK2 blockade with dichloroacetate or lentiviral PDK2 knockdown prevented ΔΨm hyperpolarization, facilitated apoptosis and reduced myointima formation in injured human mammary and coronary arteries, rat aortas, rabbit iliac arteries and swine (pig) coronary arteries. In contrast to several commonly used antiproliferative drugs, dichloroacetate did not prevent vessel re-endothelialization. Targeting myointimal ΔΨm and alleviating apoptosis resistance is a novel strategy for the prevention of proliferative vascular diseases.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24747400 PMCID: PMC4323184 DOI: 10.1038/nature13232
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962